However, the abnormal activation alone HSF1 is not sufficient to cause cancer initiation [48], which means that the pro-tumorigenesis effect of HSF1 requires the contributions of other cancer-promoting mechanisms (such as the KRAS oncogene mutation). The gene discussed is KRAS; the disease is cancer.